BRISBANE, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical firm growing a brand new class of complement medicines for sufferers with classical complement-mediated autoimmune, neurodegenerative and ophthalmic problems, at present introduced that it has granted fairness inducement awards to three new non-executive workers underneath the phrases of the 2022 Employment Inducement Award Plan. The fairness awards have been permitted on September 15, 2022, in accordance with Nasdaq Listing Rule 5635(c)(4).
In the combination, the brand new non-executive workers acquired choices to buy 125,000 shares of Annexon frequent inventory. The choices carry a ten-year time period and an train worth per share equal to $6.34, which was the closing worth of Annexon’s frequent inventory on September 15, 2022, the date of grant. The choices vest over 4 years, with 25% of the shares underlying the choices vesting on the primary anniversary of every worker’s employment begin date, and a further 1/forty eighth of the shares vesting month-to-month thereafter, topic to continued service by the relevant vesting dates.
About Annexon
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical firm that goals to carry game-changing medicines to sufferers with classical complement-mediated ailments of the physique, mind and eye. The classical complement cascade is a seminal pathway throughout the immune system that anchors and drives a number of autoimmune, neurodegenerative and ophthalmic ailments. Annexon is advancing a brand new class of complement medicines concentrating on the early classical cascade and all downstream pathway parts that contribute to illness, whereas selectively preserving the helpful immune capabilities of different complement pathways. Annexon is rigorously growing a pipeline of diversified product candidates throughout a number of mid- to late-stage scientific trials, with scientific knowledge anticipated all through 2022 and 2023.
Investor Contact:
Chelcie Lister
THRUST Strategic Communications
[email protected]
